Corrigendum to "Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6"[Clinical Lymphoma Myeloma and Leukemia 26 (2026) 317-327].
Publication/Presentation Date
9-16-2026
ISSN
2152-2669
Published In/Presented At
Andorsky, D., Lopez, A. T., Vaidya, R., Madueno, F. V., Ibrahimi, S., Naik, S., Gandhi, M., Haydu, J. E., Lash, B., Fesler, M., Hrom, J., Lee, E. H., Sundaram, S., Conte, K., Osei-Bonsu, K., Doerr, T., Bai, Y., Dixit, N., Eskelund, C. W., Boardman, A. P., … Sharman, J. P. (2026). Corrigendum to "Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6"[Clinical Lymphoma Myeloma and Leukemia 26 (2026) 317-327]. Clinical lymphoma, myeloma & leukemia, S2152-2650(26)00267-3. Advance online publication. https://doi.org/10.1016/j.clml.2026.08.006
Disciplines
Medicine and Health Sciences
PubMedID
42749555
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article